Data from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial

Read full text Summarise with VIRAT
Authors: Susanne A. Gatz, Pablo Berlanga, Gwénaël Le Teuff, Ivan Valiev, Amaury Leruste, Nicolás André, Dominique Bluteau, Nadège Corradini, Jonathan Rubino, Fabienne Thomas, Souad Nebchi, Eleni Karamouza
+27 more Jeanne Petit, Estelle Thébaud, Alba Rubio-San-Simón, Natasha K.A. van Eijkelenburg, Lynley V. Marshall, Sandra Raimbault, Adela Canete, Stephane Ducassou, Guy Makin, Michela Casanova, Émilie De Carli, Arnaud Petit, Melis Cardon, Ludovic Lacroix, Gaëlle Pierron, Gudrun Schleiermacher, Michael J.F. Hubank, Aroa Soriano, Karin P.S. Langenberg, David Castel, Tiphaine Adam-de Beaumais, Xavier Paolettí, Pradeep B. Lukka, Richard Baldry, Peter G. S. Mortimer, Sergey I. Nikolaev, Birgit Geoerger
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

AbstractPurpose: Arm D of the AcSé-ESMART proof-of-concept phase I/II platform trial aimed to define the recommended phase II dose (RP2D), pharmacokinetics, activity, and biomarkers of the PARP inhibitor olaparib with irinotecan in pediatric patients with recurrent/refractory malignancies. Patients and Methods: Olaparib was administered orally twice daily on days 1 to 10 and irinotecan intravenously on days 4 to 8 of a 21-day cycle. Dose escalation followed the continuous reassessment method; activity was assessed in diverse tumor types (cohort 1) and Ewing sarcoma (cohort 2) according to a minimax Simon 2-stage design. Cohorts were enriched for alterations in homologous recombination repair (HRR) pathways. Results: Seventy patients (median age, 14.9 years; range, 5.0–23.8) were included, 34 with diverse tumor types (25 with HRR gene alterations) and 36 with Ewing sarcoma. Sixty-six patients received 348 treatment cycles (median, 2; range, 1–51) over four dose levels. Main toxicities were gastrointestinal and myelosuppression; the RP2D was olaparib 90 mg/m2 twice daily and irinotecan 20 mg/m2/day. Olaparib exposure in children was equivalent to that in adults. The overall response rate was 9.1% (cohort 1, 11.8%; cohort 2, 6.3%). Four patients with osteosarcoma, pineoblastoma, choroid plexus carcinoma, and neuroblastoma experienced a partial response and were treated for nine to 51 cycles. Two patients with Ewing sarcoma experienced a complete and a partial response for 10 and 42 cycles, respectively. Genetic analyses suggest a high aneuploidy score possibly associated with objective response and prolonged stable disease. Conclusions: Olaparib combined with irinotecan demonstrated activity in pediatric tumors, which was enriched among tumors that exhibited aneuploidy.

Fields of Study & Subjects

PARP inhibition in cancer therapy Acute Lymphoblastic Leukemia research BRCA gene mutations in cancer

Publication details

Publication date
1 April 2026
Language
EN